-
-
-
-
-
-
-
Dianthus presents new data on claseprubart for myasthenia gravis
-
-
-
-
-
-
-
Dianthus Therapeutics (DNTH) PT Raised to $66 at Jefferies, 'We believe DNTH is undervalued'
-
-
-
-
-
-
-
Dianthus Therapeutics (DNTH) PT Raised to $92 at Guggenheim
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Dianthus Therapeutics (DNTH)
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Dianthus Therapeutics (DNTH)
-
-
-
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

